The bacterial etiology and antimicrobial susceptibility of lower respiratory tract infections in Vietnam
Carbapenem-resistant Gram-negative pathogens were predominant among hospital-acquired LRTIs in Vietnam, with notable resistance to ceftazidime-avibactam and colistin. The lack of effective treatment for A. baumannii remains a major concern. We found a strong correlation between AMR phenotype and genotype among K. pneumoniae and E. coli, supporting gene-based therapy to guide ceftazidime-avibactam use. However, the presence of disrupted bla<sub>NDM</sub> underscores the need to re-evaluate commercial PCR assays for carbapenemase detection.
Authors
- Trần Thị Ngọc Dung (ORCID: https://orcid.org/0000-0002-1935-7777)
- Phạm Hồng Ánh
- Van Dinh Trang
- Guy Edward Thwaites (ORCID: https://orcid.org/0000-0002-2858-2087)
- Vinh Chau (ORCID: https://orcid.org/0000-0001-6634-7267)
- H. Rogier van Doorn (ORCID: https://orcid.org/0000-0002-9807-1821)
- Nguyen Phu Huong Lan (ORCID: https://orcid.org/0000-0002-9551-2302)
- Pham Thi Thanh Tam
- Thomas Kesteman (ORCID: https://orcid.org/0000-0002-7951-8261)
- Trương Thiên Phú (ORCID: https://orcid.org/0000-0003-0868-2811)
- Quynh Nguyen (ORCID: https://orcid.org/0000-0002-5975-3600)
- Duy Pham Thanh (ORCID: https://orcid.org/0000-0001-7029-9210)
- Nguyen Thi Phuoc Van (ORCID: https://orcid.org/0000-0002-1702-0230)
- Ha Thanh Tuyen
- Nguyen Su Minh Tuyet
- Hong Nhung Pham (ORCID: https://orcid.org/0000-0002-4543-8386)
- Nguyễn Thị Thanh
- Vo Kim Phuong Linh
Institutions
- Hanoi Medical University (VN)
- Cho Ray Hospital (VN)
- University of Oxford (GB)
- Khanh Hoa General Hospital (VN)
- Oxford University Clinical Research Unit (VN)
- Bạch Mai Hospital (VN)
- Viet Duc Hospital (VN)
- Hospital for Tropical Diseases (VN)
- Pham Ngoc Thach Hospital (VN)
Publication Details
- Journal
- Annals of Clinical Microbiology and Antimicrobials
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1186/s12941-025-00818-3
- Citations
- 1
- Primary Topic
- Antibiotic Use and Resistance
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Pfizer